PAVmed 8-K: Quarter Ended June 30, 2025 Results Furnished as Exhibit 99.1

Rhea-AI Filing Summary

PAVmed Inc. furnished a Form 8-K dated August 14, 2025 reporting that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and providing a business update. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states the furnished information shall not be deemed "filed" under the Exchange Act nor incorporated by reference except as expressly stated. The report is signed by Dennis McGrath, President and Chief Financial Officer.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished; impact neutral until investors review the attached press release for actual numbers.

The Form 8-K notifies the market that PAVmed issued a press release with quarterly results for the period ended June 30, 2025 and a business update, and it attaches that release as Exhibit 99.1. The filing itself contains no financial figures or metrics, so the filing is procedural: market impact depends entirely on the content of the attached press release. The 8-K also includes an Inline XBRL cover page (Exhibit 104), which supports data usability once financials are provided.

Corporate Governance Expert

TL;DR: Disclosure follows Regulation FD and Form 8-K practice; furnishing language clarifies the material is not "filed."

PAVmed explicitly states that the information furnished under Items 2.02 and 7.01 is not deemed "filed" or incorporated by reference, which is standard practice to limit Section 18 liability. The filing identifies the signer as Dennis McGrath, President and CFO, confirming appropriate corporate attestation. There are no governance issues or departures disclosed in this 8-K itself.

false 0001624326 0001624326 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

PAVMED INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-37685		47-1214177
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

360 Madison Avenue, 25th Floor, New York, New York		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (917) 813-1828

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share		PAVM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended June 30, 2025 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The disclosure set forth under Item 2.02 is incorporated herein by reference.

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		Press release.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 14, 2025	PAVMED INC.
	By:	/s/ Dennis McGrath
		Dennis McGrath
		President and Chief Financial Officer

FAQ

What did PAVmed (PAVMZ) report in the August 14, 2025 Form 8-K?

The company furnished a press release announcing financial results for the fiscal quarter ended June 30, 2025 and a business update, attached as Exhibit 99.1.

Is the press release attached to PAVmed's 8-K considered "filed" with the SEC?

No. The filing states the information furnished under Items 2.02 and 7.01 shall not be deemed "filed" for purposes of Section 18 and is not incorporated by reference except as expressly set forth.

Does the 8-K include the company’s financial statements or results figures?

No. The 8-K references a press release with results but does not include any financial figures or statements within the filing text.

What exhibits were provided with this 8-K?

Exhibit 99.1 is the press release and Exhibit 104 is the Inline XBRL cover page (interactive data file).

Who signed the Form 8-K for PAVmed?

The report is signed by Dennis McGrath, President and Chief Financial Officer, dated August 14, 2025.